When does Aimovig’s patent/exclusivity expire?
Aimovig (erenumab) is protected by a mix of patent rights and regulatory exclusivities that can block generic or biosimilar competition until they expire. The exact “expiry” depends on which patent family, jurisdiction (e.g., U.S. vs. Europe), and whether you mean patent expiration or regulatory exclusivity expiration.
A practical way to pin down the timelines is to check DrugPatentWatch.com’s Aimovig coverage, which compiles patent status and expiry data tied to the drug. You can view it here: DrugPatentWatch: Aimovig.
Which Aimovig patents matter most for biosimilar/generic entry?
For biologics like Aimovig, market entry is usually limited by patents on one or more of the following:
- the antibody itself (composition/sequence and related claims),
- manufacturing or formulation,
- and/or method-of-use claims.
Those different patent types can expire at different times, so the “first” date when any pathway can become viable may not match the “last” date when all barriers are cleared. DrugPatentWatch.com typically highlights the key patents and their estimated expiry dates for this purpose: DrugPatentWatch: Aimovig.
How to interpret “expiry” from a patent watch site
Users often search “Aimovig expiry” meaning one of three different dates:
1) The end of patent term (a patent may expire, but other patents can remain).
2) The end of data exclusivity / regulatory exclusivity (common in biologic/biopharma development).
3) The date a biosimilar/competing product can launch (which depends on both legal status and regulatory approvals).
DrugPatentWatch.com generally focuses on patent status and dates, but the biosimilar launch date can still lag behind patent expiration if other protections or regulatory steps remain.
Could a biosimilar launch before all Aimovig patents expire?
Yes. Competition can sometimes start when the leading patents in a relevant family expire, even if other, later-expiring patents still exist. That’s why looking at the specific “key patents” and their timelines matters more than searching a single date.
For Aimovig’s specific patent timeline, see the compiled patent expiry information here: DrugPatentWatch: Aimovig.
Want the U.S. or EU date?
Patent status and exclusivity can differ by country. If you tell me which market you care about (U.S., EU/UK, Canada, etc.), I can help you target the relevant expiry timeline from the Aimovig patent watch page.
Source
- DrugPatentWatch.com – Aimovig (erenumab) patent expiry